vs

Side-by-side financial comparison of Limoneira CO (LMNR) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.

Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $41.3M, roughly 1.7× Limoneira CO). Limoneira CO runs the higher net margin — -21.0% vs -49.0%, a 28.0% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs -2.8%).

Limoneira Company is a leading agribusiness headquartered in California, the U.S. It primarily cultivates, processes and distributes premium citrus fruits, avocados and other specialty agricultural products. It operates across North American, Asian and European markets, serving retail and food service clients, alongside a sustainable land real estate development segment.

Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.

LMNR vs VRDN — Head-to-Head

Bigger by revenue
VRDN
VRDN
1.7× larger
VRDN
$70.6M
$41.3M
LMNR
Growing faster (revenue YoY)
VRDN
VRDN
+81960.9% gap
VRDN
81958.1%
-2.8%
LMNR
Higher net margin
LMNR
LMNR
28.0% more per $
LMNR
-21.0%
-49.0%
VRDN

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
LMNR
LMNR
VRDN
VRDN
Revenue
$41.3M
$70.6M
Net Profit
$-8.7M
$-34.6M
Gross Margin
-15.1%
Operating Margin
-26.8%
-56.7%
Net Margin
-21.0%
-49.0%
Revenue YoY
-2.8%
81958.1%
Net Profit YoY
-367.5%
54.9%
EPS (diluted)
$-0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LMNR
LMNR
VRDN
VRDN
Q4 25
$41.3M
Q3 25
$45.9M
$70.6M
Q2 25
$33.6M
Q1 25
$32.9M
Q4 24
$42.5M
Q3 24
$61.8M
Q2 24
$43.3M
Q1 24
$38.3M
Net Profit
LMNR
LMNR
VRDN
VRDN
Q4 25
$-8.7M
Q3 25
$-855.0K
$-34.6M
Q2 25
$-3.4M
Q1 25
$-3.1M
Q4 24
$-1.9M
Q3 24
$6.6M
Q2 24
$6.6M
Q1 24
$-3.6M
Gross Margin
LMNR
LMNR
VRDN
VRDN
Q4 25
-15.1%
Q3 25
8.5%
Q2 25
5.6%
Q1 25
-2.0%
Q4 24
6.3%
Q3 24
26.5%
Q2 24
6.5%
Q1 24
-2.0%
Operating Margin
LMNR
LMNR
VRDN
VRDN
Q4 25
-26.8%
Q3 25
-1.4%
-56.7%
Q2 25
-10.0%
Q1 25
-16.3%
Q4 24
-6.5%
Q3 24
14.5%
Q2 24
-10.8%
Q1 24
-20.2%
Net Margin
LMNR
LMNR
VRDN
VRDN
Q4 25
-21.0%
Q3 25
-1.9%
-49.0%
Q2 25
-10.0%
Q1 25
-9.4%
Q4 24
-4.4%
Q3 24
10.7%
Q2 24
15.2%
Q1 24
-9.4%
EPS (diluted)
LMNR
LMNR
VRDN
VRDN
Q4 25
$-0.49
Q3 25
$-0.06
Q2 25
$-0.20
Q1 25
$-0.18
Q4 24
$-0.09
Q3 24
$0.35
Q2 24
$0.35
Q1 24
$-0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LMNR
LMNR
VRDN
VRDN
Cash + ST InvestmentsLiquidity on hand
$490.9M
Total DebtLower is stronger
$72.5M
Stockholders' EquityBook value
$180.0M
$503.0M
Total Assets
$311.1M
$577.1M
Debt / EquityLower = less leverage
0.40×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LMNR
LMNR
VRDN
VRDN
Q4 25
Q3 25
$490.9M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Total Debt
LMNR
LMNR
VRDN
VRDN
Q4 25
$72.5M
Q3 25
$63.4M
Q2 25
$55.0M
Q1 25
$58.0M
Q4 24
$40.6M
Q3 24
$40.6M
Q2 24
$60.1M
Q1 24
$52.1M
Stockholders' Equity
LMNR
LMNR
VRDN
VRDN
Q4 25
$180.0M
Q3 25
$180.3M
$503.0M
Q2 25
$182.7M
Q1 25
$186.5M
Q4 24
$191.7M
Q3 24
$194.9M
Q2 24
$189.0M
Q1 24
$184.2M
Total Assets
LMNR
LMNR
VRDN
VRDN
Q4 25
$311.1M
Q3 25
$299.9M
$577.1M
Q2 25
$296.6M
Q1 25
$301.4M
Q4 24
$298.8M
Q3 24
$307.3M
Q2 24
$322.2M
Q1 24
$299.6M
Debt / Equity
LMNR
LMNR
VRDN
VRDN
Q4 25
0.40×
Q3 25
0.35×
Q2 25
0.30×
Q1 25
0.31×
Q4 24
0.21×
Q3 24
0.21×
Q2 24
0.32×
Q1 24
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LMNR
LMNR
VRDN
VRDN
Operating Cash FlowLast quarter
$942.0K
$-84.6M
Free Cash FlowOCF − Capex
$-84.7M
FCF MarginFCF / Revenue
-120.1%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LMNR
LMNR
VRDN
VRDN
Q4 25
$942.0K
Q3 25
$-3.0M
$-84.6M
Q2 25
$8.9M
Q1 25
$-12.9M
Q4 24
$6.6M
Q3 24
$24.6M
Q2 24
$-3.0M
Q1 24
$-10.3M
Free Cash Flow
LMNR
LMNR
VRDN
VRDN
Q4 25
Q3 25
$-84.7M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
FCF Margin
LMNR
LMNR
VRDN
VRDN
Q4 25
Q3 25
-120.1%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Capex Intensity
LMNR
LMNR
VRDN
VRDN
Q4 25
Q3 25
0.2%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Cash Conversion
LMNR
LMNR
VRDN
VRDN
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
3.73×
Q2 24
-0.46×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LMNR
LMNR

Lemon Packing$33.9M82%
Other Agribusiness$5.8M14%
Fresh Lemons$1.3M3%

VRDN
VRDN

Segment breakdown not available.

Related Comparisons